Lymphangioleiomyomatosis (LAM): Molecular insights lead to targeted therapies

Respiratory Medicine

Volumn 104, Issue SUPPL. 1, 2010, Pages

  Glasgow, Connie G ^a   Steagall, Wendy K ^a   Taveira DaSilva, Angelo ^a   Pacheco Rodriguez, Gustavo ^a   Cai, Xiong ^a   El Chemaly, Souheil ^a   Moses, Marsha ^b   Darling, Thomas ^c   Moss, Joel ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

Lymphangioleiomyomatosis; Lymphatics; Mammalian target of rapamycin (mTOR); Metastasis; Sirolimus; Tuberous sclerosis complex (TSC)

Indexed keywords

CD44V6 ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIN DEPENDENT KINASE 2 INHIBITOR; ESTROGEN; GELATINASE A; GELATINASE B; GONADORELIN DERIVATIVE; HERMES ANTIGEN; INTERSTITIAL COLLAGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MONOCLONAL ANTIBODY HMB 45; PROGESTERONE; RAPAMYCIN; ROSCOVITINE; TEMSIROLIMUS; TUBERIN; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ABDOMINAL TUMOR; ANGIOMYOLIPOMA; ARTICLE; CARDIOPULMONARY EXERCISE TEST; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYSTADENOMA; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; GENE MUTATION; HUMAN; KIDNEY CYST; LUNG DIFFUSION CAPACITY; LUNG METASTASIS; LUNG NODULE; LUNG TRANSPLANTATION; LYMPHANGIOLEIOMYOMATOSIS; NONHUMAN; OVARIECTOMY; PATHOGENESIS; PNEUMOTHORAX; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUBEROUS SCLEROSIS;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; PHENOTYPE; PROGNOSIS; RARE DISEASES; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77953005726     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2010.03.017     Document Type: Article

References (163)

1. Kitaichi M., Nishimura K., Itoh H., and Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 151 2 Pt 1 (1995 Feb) 527-533
2. Chu S.C., Horiba K., Usuki J., Avila N.A., Chen C.C., Travis W.D., et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 115 4 (1999 Apr) 1041-1052
3. Urban T., Lazor R., Lacronique J., Murris M., Labrune S., Valeyre D., et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P). Medicine (Baltimore) 78 5 (1999 Sep) 321-337
4. Johnson S.R., and Tattersfield A.E. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 55 12 (2000 Dec) 1052-1057
5. Ryu J.H., Moss J., Beck G.J., Lee J.C., Brown K.K., Chapman J.T., et al. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 173 1 (2006 Jan 1) 105-111
6. Taveira-DaSilva A.M., Steagall W.K., and Moss J. Lymphangioleiomyomatosis. Cancer Control 13 4 (2006 Oct) 276-285
7. Johnson S.R., Whale C.I., Hubbard R.B., Lewis S.A., and Tattersfield A.E. Survival and disease progression in UK patients with lymphangioleiomyomatosis. Thorax 59 9 (2004 Sep) 800-803
8. Taveira-DaSilva A.M., Hedin C., Stylianou M.P., Travis W.D., Matsui K., Ferrans V.J., et al. Reversible airflow obstruction, proliferation of abnormal smooth muscle cells, and impairment of gas exchange as predictors of outcome in lymphangioleiomyomatosis. Am J Respir Crit Care Med 164 6 (2001 Sep 15) 1072-1076
9. Avila N.A., Chen C.C., Chu S.C., Wu M., Jones E.C., Neumann R.D., et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology 214 2 (2000 Feb) 441-446
10. Ferrans V.J., Yu Z.X., Nelson W.K., Valencia J.C., Tatsuguchi A., Avila N.A., et al. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 67 5 (2000 Oct) 311-329
11. Smolarek T.A., Wessner L.L., McCormack F.X., Mylet J.C., Menon A.G., and Henske E.P. Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet. 62 4 (1998 Apr) 810-815
12. Carsillo T., Astrinidis A., and Henske E.P. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97 11 (2000 May 23) 6085-6090
13. Sato T., Seyama K., Fujii H., Maruyama H., Setoguchi Y., Iwakami S., et al. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis. J Hum Genet 47 1 (2002) 20-28
14. Matsumoto Y., Horiba K., Usuki J., Chu S.C., Ferrans V.J., and Moss J. Markers of cell proliferation and expression of melanosomal antigen in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 21 3 (1999 Sep) 327-336
15. Matsui K., Tatsuguchi A., Valencia J., Yu Z., Bechtle J., Beasley M.B., et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 31 10 (2000 Oct) 1242-1248
16. Kelly J., and Moss J. Lymphangioleiomyomatosis. Am J Med Sci 321 1 (2001 Jan) 17-25
17. Maziak D.E., Kesten S., Rappaport D.C., and Maurer J. Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Eur Respir J 9 3 (1996 Mar) 402-405
18. Matsui K., Hilbert S.L., W Kr, Yu Z.X., Takeda K., Travis W.D., et al. Hyperplasia of type II pneumocytes in pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124 11 (2000 Nov) 1642-1648
19. Osborne J.P., Fryer A., and Webb D. Epidemiology of tuberous sclerosis. Ann N Y Acad Sci 615 (1991) 125-127
20. Sampson J.R., and Harris P.C. The molecular genetics of tuberous sclerosis. Hum Mol Genet 3 Spec No (1994) 1477-1480
21. Franz D.N., Brody A., Meyer C., Leonard J., Chuck G., Dabora S., et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 164 4 (2001 Aug 15) 661-668
22. Moss J., Avila N.A., Barnes P.M., Litzenberger R.A., Bechtle J., Brooks P.G., et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 164 4 (2001 Aug 15) 669-671
23. Costello L.C., Hartman T.E., and Ryu J.H. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 75 6 (2000 Jun) 591-594
24. Bittmann I., Rolf B., Amann G., and Lohrs U. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 34 1 (2003 Jan) 95-98
25. Karbowniczek M., Astrinidis A., Balsara B.R., Testa J.R., Lium J.H., Colby T.V., et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 167 7 (2003 Apr 1) 976-982
26. Crooks D.M., Pacheco-Rodriguez G., DeCastro R.M., McCoy Jr. J.P., Wang J.A., Kumaki F., et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 101 50 (2004 Dec 14) 17462-17467
27. Matsui K., Beasley M.B., Nelson W.K., Barnes P.M., Bechtle J., Falk R., et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 25 4 (2001 Apr) 479-484
28. Avila N.A., Kelly J.A., Dwyer A.J., Johnson D.L., Jones E.C., and Moss J. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology 223 1 (2002 Apr) 189-197
29. Crausman R.S., Lynch D.A., Mortenson R.L., King Jr. T.E., Irvin C.G., Hale V.A., et al. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis. Chest 109 1 (1996 Jan) 131-137
30. Paciocco G., Uslenghi E., Bianchi A., Mazzarella G., Roviaro G.C., Vecchi G., et al. Diffuse cystic lung diseases: correlation between radiologic and functional status. Chest 125 1 (2004 Jan) 135-142
31. Schmithorst V.J., Altes T.A., Young L.R., Franz D.N., Bissler J.J., McCormack F.X., et al. Automated algorithm for quantifying the extent of cystic change on volumetric chest CT: initial results in Lymphangioleiomyomatosis. AJR Am J Roentgenol 192 4 (2009) 1037-1044
32. Taveira-DaSilva A.M., Stylianou M.P., Hedin C.J., Hathaway O., and Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 126 6 (2004 Dec) 1867-1874
33. Taveira-DaSilva A.M., Stylianou M.P., Hedin C.J., Kristof A.S., Avila N.A., Rabel A., et al. Maximal oxygen uptake and severity of disease in lymphangioleiomyomatosis. Am J Respir Crit Care Med 168 12 (2003 Dec 15) 1427-1431
34. Crausman R.S., Jennings C.A., Mortenson R.L., Ackerson L.M., Irvin C.G., and King Jr. T.E. Lymphangioleiomyomatosis: the pathophysiology of diminished exercise capacity. Am J Respir Crit Care Med 153 4 Pt 1 (1996 Apr) 1368-1376
35. Taveira-DaSilva A.M., Hathaway O.M., Sachdev V., Shizukuda Y., Birdsall C.W., and Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 132 5 (2007 Nov) 1573-1578
36. Eaton T., Young P., Milne D., and Wells A.U. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171 10 (2005 May 15) 1150-1157
37. Johnson S.R., and Tattersfield A.E. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 160 2 (1999 Aug) 628-633
38. Lazor R., Valeyre D., Lacronique J., Wallaert B., Urban T., and Cordier J.F. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 98 6 (2004 Jun) 536-541
39. Hayashida M., Seyama K., Inoue Y., Fujimoto K., and Kubo K. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross-sectional study of presenting features and prognostic factors. Respirology 12 4 (2007 Jul) 523-530
40. Colley M.H., Geppert E., and Franklin W.A. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol 13 9 (1989 Sep) 803-807
41. Berger U., Khaghani A., Pomerance A., Yacoub M.H., and Coombes R.C. Pulmonary lymphangioleiomyomatosis and steroid receptors. An immunocytochemical study. Am J Clin Pathol 93 5 (1990 May) 609-614
42. Ohori N.P., Yousem S.A., Sonmez-Alpan E., and Colby T.V. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol 96 4 (1991 Oct) 529-535
43. Yockey C.C., Riepe R.E., and Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med 87 10 (1986 Oct) 277-278 93
44. Brunelli A., Catalini G., and Fianchini A. Pregnancy exacerbating unsuspected mediastinal lymphangioleiomyomatosis and chylothorax. Int J Gynaecol Obstet 52 3 (1996 Mar) 289-290
45. Shen A., Iseman M.D., Waldron J.A., and King T.E. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 91 5 (1987 May) 782-785
46. Yano S. Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous oestrogen used for infertility treatment. Thorax 57 12 (2002 Dec) 1085-1086
47. Oberstein E.M., Fleming L.E., Gomez-Marin O., and Glassberg M.K. Pulmonary lymphangioleiomyomatosis (LAM): examining oral contraceptive pills and the onset of disease. J Womens Health (Larchmt) 12 1 (2003 Jan-Feb) 81-85
48. Wahedna I., Cooper S., Williams J., Paterson I.C., Britton J.R., and Tattersfield A.E. Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax 49 9 (1994 Sep) 910-914
49. Taylor J.R., Ryu J., Colby T.V., and RaffinLymphangioleiomyomatosis T.A. Clinical course in 32 patients. N Engl J Med 323 18 (1990 Nov 1) 1254-1260
50. Rossi G.A., Balbi B., Oddera S., Lantero S., and Ravazzoni C. Response to treatment with an analog of the luteinizing-hormone-releasing hormone in a patient with pulmonary lymphangioleiomyomatosis. Am Rev Respir Dis 143 1 (1991 Jan) 174-176
51. Desurmont S., Bauters C., Copin M.C., Dewailly D., Tonnel A.B., and Wallaert B. Treatment of pulmonary lymphangioleiomyomatosis using a GnRH agonist. Rev Mal Respir 13 3 (1996 Jul) 300-304
52. Medeiros Jr. P. Evaluation of functional pulmonary response to gonadotrophin releasing hormone agonist (goserelin) in the treatment of lymphangioleiomyomatosis. Am J Respir Crit Care Medicine 165 (2002) A701
53. de la Fuente J., Paramo C., Roman F., Perez R., Masa C., and de Letona J.M. Lymphangioleiomyomatosis: unsuccessful treatment with luteinizing-hormone-releasing hormone analogues. Eur J Med 2 6 (1993 Jun-Jul) 377-378
54. Harari S., Cassandro R., Chiodini J., Taveira-DaSilva A.M., and Moss J. Effect of a gonadotrophin-releasing hormone analogue on lung function in lymphangioleiomyomatosis. Chest 133 2 (2008 Feb) 448-454
55. Yu J.J., Robb V.A., Morrison T.A., Ariazi E.A., Karbowniczek M., Astrinidis A., et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 106 8 (2009 Feb 24) 2635-2640
56. Glassberg M.K., Elliot S.J., Fritz J., Catanuto P., Potier M., Donahue R., et al. Activation of the estrogen receptor contributes to the progression of pulmonary lymphangioleiomyomatosis via matrix metalloproteinase-induced cell invasiveness. J Clin Endocrinol Metab 93 5 (2008 May) 1625-1633
57. Clements D., Asprey S.L., McCulloch T.A., Morris T.A., Watson S.A., and Johnson S.R. Analysis of the oestrogen response in an angiomyolipoma derived xenograft model. Endocr Relat Cancer 16 1 (2009 Mar) 59-72
58. Almoosa K.F., McCormack F.X., and Sahn S.A. Pleural disease in lymphangioleiomyomatosis. Clin Chest Med 27 2 (2006 Jun) 355-368
59. Steagall W.K., Glasgow C.G., Hathaway O.M., Avila N.A., Taveira-Dasilva A.M., Rabel A., et al. Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis. Am J Physiol Lung Cell Mol Physiol 293 3 (2007 Sep) L800-L808
60. Suki B., Ito S., Stamenovic D., Lutchen K.R., and Ingenito E.P. Biomechanics of the lung parenchyma: critical roles of collagen and mechanical forces. J Appl Physiol 98 5 (2005 May) 1892-1899
61. Fukuda Y., Kawamoto M., Yamamoto A., Ishizaki M., Basset F., and Masugi Y. Role of elastic fiber degradation in emphysema-like lesions of pulmonary lymphangiomyomatosis. Hum Pathol 21 12 (1990 Dec) 1252-1261
62. Hayashi T., Fleming M.V., Stetler-Stevenson W.G., Liotta L.A., Moss J., Ferrans V.J., et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 28 9 (1997 Sep) 1071-1078
63. Matsui K., Takeda K., Yu Z.X., Travis W.D., Moss J., and Ferrans V.J. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124 2 (2000 Feb) 267-275
64. Avila N.A., Kelly J.A., Chu S.C., Dwyer A.J., and Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 216 1 (2000 Jul) 147-153
65. Avila N.A., Bechtle J., Dwyer A.J., Ferrans V.J., and Moss J. Lymphangioleiomyomatosis: CT of diurnal variation of lymphangioleiomyomas. Radiology 221 2 (2001 Nov) 415-421
66. Avila N.A., Dwyer A.J., Murphy-Johnson D.V., Brooks P., and Moss J. Sonography of lymphangioleiomyoma in lymphangioleiomyomatosis: demonstration of diurnal variation in lesion size. AJR Am J Roentgenol 184 2 (2005 Feb) 459-464
67. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci U S A 92 8 (1995 Apr 11) 3566-3570
68. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 12 (1996 Dec) 3829-3837
69. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7 2 (2001 Feb) 186-191
70. Jussila L., and Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 82 3 (2002 Jul) 673-700
71. Kumasaka T., Seyama K., Mitani K., Sato T., Souma S., Kondo T., et al. Lymphangiogenesis in lymphangioleiomyomatosis: its implication in the progression of lymphangioleiomyomatosis. Am J Surg Pathol 28 8 (2004 Aug) 1007-1016
72. Kumasaka T., Seyama K., Mitani K., Souma S., Kashiwagi S., Hebisawa A., et al. Lymphangiogenesis-mediated shedding of LAM cell clusters as a mechanism for dissemination in lymphangioleiomyomatosis. Am J Surg Pathol 29 10 (2005 Oct) 1356-1366
73. Seyama K., Kumasaka T., Souma S., Sato T., Kurihara M., Mitani K., et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol 4 3 (2006) 143-152
74. Glasgow C.G., Avila N.A., Lin J.P., Stylianou M.P., and Moss J. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest 135 5 (2009 May) 1293-1300
75. Young L.R., Inoue Y., and McCormack F.X. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med 358 2 (2008 Jan 10) 199-200
76. Achen M.G., Roufail S., Domagala T., Catimel B., Nice E.C., Geleick D.M., et al. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur J Biochem 267 9 (2000 May) 2505-2515
77. Stacker S.A., and Achen M.G. From anti-angiogenesis to anti-lymphangiogenesis: emerging trends in cancer therapy. Lymphat Res Biol 6 3-4 (2008) 165-172
78. Hanrahan E.O., and Heymach J.V. Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. Clin Cancer Res 13 15 Pt 2 (2007 Aug 1) s4617-s4622
79. Henske E.P. Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38 4 (2003 Dec) 376-381
80. Langley R.R., and Fidler I.J. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 28 3 (2007 May) 297-321
81. Ponta H., Sherman L., and Herrlich P.A. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4 1 (2003 Jan) 33-45
82. Heider K.H., Kuthan H., Stehle G., and Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother 53 7 (2004 Jul) 567-579
83. Cheng C., Yaffe M.B., and Sharp P.A. A positive feedback loop couples Ras activation and CD44 alternative splicing. Genes Dev 20 13 (2006 Jul 1) 1715-1720
84. Cheng C., and Sharp P.A. Regulation of CD44 alternative splicing by SRm160 and its potential role in tumor cell invasion. Mol Cell Biol 26 1 (2006 Jan) 362-370
85. Matter N., Herrlich P., and Konig H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 420 6916 (2002 Dec 12) 691-695
86. Noda M., Yoon K., Prince C.W., Butler W.T., and Rodan G.A. Transcriptional regulation of osteopontin production in rat osteosarcoma cells by type beta transforming growth factor. J Biol Chem 263 27 (1988 Sep 25) 13916-13921
87. Atkins K.B., Simpson R.U., and Somerman M.J. Stimulation of osteopontin mRNA expression in HL-60 cells is independent of differentiation. Arch Biochem Biophys 343 2 (1997 Jul 15) 157-163
88. Omigbodun A., Ziolkiewicz P., Tessler C., Hoyer J.R., and Coutifaris C. Progesterone regulates osteopontin expression in human trophoblasts: a model of paracrine control in the placenta?. Endocrinology 138 10 (1997 Oct) 4308-4315
89. Katagiri Y.U., Sleeman J., Fujii H., Herrlich P., Hotta H., Tanaka K., et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 59 1 (1999 Jan 1) 219-226
90. Gao C., Guo H., Downey L., Marroquin C., Wei J., and Kuo P.C. Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24 12 (2003 Dec) 1871-1878
91. Pacheco-Rodriguez G., Steagall W.K., Crooks D.M., Stevens L.A., Hashimoto H., Li S., et al. TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis. Cancer Res 67 21 (2007 Nov 1) 10573-10581
92. Nagano O., and Saya H. Mechanism and biological significance of CD44 cleavage. Cancer Sci 95 12 (2004 Dec) 930-935
93. Anderegg U., Eichenberg T., Parthaune T., Haiduk C., Saalbach A., Milkova L., et al. ADAM10 is the constitutive functional sheddase of CD44 in human melanoma cells. J Invest Dermatol 129 6 (2009 Jun) 1471-1482
94. Gunthert U., Hofmann M., Rudy W., Reber S., Zoller M., Haussmann I., et al. A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65 1 (1991 Apr 5) 13-24
95. Reeder J.A., Gotley D.C., Walsh M.D., Fawcett J., and Antalis T.M. Expression of antisense CD44 variant 6 inhibits colorectal tumor metastasis and tumor growth in a wound environment. Cancer Res 58 16 (1998 Aug 15) 3719-3726
96. Harada N., Mizoi T., Kinouchi M., Hoshi K., Ishii S., Shiiba K., et al. Introduction of antisense CD44S CDNA down-regulates expression of overall CD44 isoforms and inhibits tumor growth and metastasis in highly metastatic colon carcinoma cells. Int J Cancer 91 1 (2001 Jan 1) 67-75
97. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nature Med 12 10 (2006) 1167-1174
98. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 6824 (2001 Mar 1) 50-56
99. Pacheco-Rodriguez G., Kumaki F., Steagall W.K., Zhang Y., Ikeda Y., Lin J.P., et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol 182 3 (2009 Feb 1) 1270-1277
100. Li S., Takeuchi F., Wang J.A., Fuller C., Pacheco-Rodriguez G., Moss J., et al. MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med 202 5 (2005 Sep 5) 617-624
101. Wu X., Lee V.C., Chevalier E., and Hwang S.T. Chemokine receptors as targets for cancer therapy. Curr Pharm Des 15 7 (2009) 742-757
102. Dawson J., Miltz W., Mir A.K., and Wiessner C. Targeting monocyte chemoattractant protein-1 signalling in disease. Expert Opin Ther Targets 7 1 (2003 Feb) 35-48
103. Dol F., Martin G., Staels B., Mares A.M., Cazaubon C., Nisato D., et al. Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38 3 (2001 Sep) 395-405
104. Nagase H. Matrix metalloproteinases. In: HN M. (Ed). Zinc metalloproteases in health and disease (1996), Taylor and Frances, London 153-204
105. Kleiner D.E., and Stetler-Stevenson W.G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 43 Suppl (1999) S42-51
106. La Rocca G., Pucci-Minafra I., Marrazzo A., Taormina P., and Minafra S. Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera. Br J Cancer 90 7 (2004 Apr 5) 1414-1421
107. Koc M., Ediger D., Budak F., Karadag M., Oral H.B., Uzaslan E., et al. Matrix metalloproteinase-9 (MMP-9) elevated in serum but not in bronchial lavage fluid in patients with lung cancer. Tumori 92 2 (2006 Mar-Apr) 149-154
108. O-Charoenrat P., Rhys-Evans P.H., and Eccles S.A. Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 127 7 (2001 Jul) 813-820
109. Tamura M., Oda M., Matsumoto I., Tsunezuka Y., Kawakami K., Ohta Y., et al. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer. Ann Surg Oncol 11 10 (2004 Oct) 928-933
110. Tutton M.G., George M.L., Eccles S.A., Burton S., Swift R.I., and Abulafi A.M. Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. Int J Cancer 107 4 (2003 Nov 20) 541-550
111. Mylona E., Nomikos A., Magkou C., Kamberou M., Papassideri I., Keramopoulos A., et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology 50 3 (2007 Feb) 338-347
112. Moses M.A., Wiederschain D., Loughlin K.R., Zurakowski D., Lamb C.C., and Freeman M.R. Increased incidence of matrix metalloproteinases in urine of cancer patients. Cancer Res 58 7 (1998 Apr 1) 1395-1399
113. Gilbertson-Beadling S., Powers E.A., Stamp-Cole M., Scott P.S., Wallace T.L., Copeland J., et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol 36 5 (1995) 418-424
114. Ji R.C. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. Lymphat Res Biol 4 2 (2006) 83-100
115. Moses M.A., Harper J., and Folkman J. Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med 354 24 (2006 Jun 15) 2621-2622
116. Yan L., Borregaard N., Kjeldsen L., and Moses M.A. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 276 40 (2001 Oct 5) 37258-37265
117. Burgstaller S., Rosner M., Lindengrun C., Hanneder M., Siegel N., Valli A., et al. Tuberin, p27 and MTOR in different cells. Amino Acids 36 2 (2009 Feb) 297-302
118. Hong F., Larrea M.D., Doughty C., Kwiatkowski D.J., Squillace R., and Slingerland J.M. MTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30 6 (2008 Jun 20) 701-711
119. Short J.D., Houston K.D., Dere R., Cai S.L., Kim J., Johnson C.L., et al. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Res 68 16 (2008 Aug 15) 6496-6506
120. Rosner M., and Hengstschlager M. Tuberin binds p27 and negatively regulates its interaction with the SCF component Skp2. J Biol Chem 279 47 (2004 Nov 19) 48707-48715
121. Soucek T., Rosner M., Miloloza A., Kubista M., Cheadle J.P., Sampson J.R., et al. Tuberous sclerosis causing mutants of the TSC2 gene product affect proliferation and p27 expression. Oncogene 20 35 (2001 Aug 9) 4904-4909
122. Malumbres M., and Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9 3 (2009 Mar) 153-166
123. Polak P., and Hall M.N. MTOR and the control of whole body metabolism. Curr Opin Cell Biol 21 2 (2009 Apr) 209-218
124. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., et al. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 10 3 (2002 Sep) 457-468
125. Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., et al. Rictor, a novel binding partner of MTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 14 14 (2004 Jul 27) 1296-1302
126. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 110 2 (2002 Jul 26) 177-189
127. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., et al. Prolonged rapamycin treatment inhibits MTORC2 assembly and Akt/PKB. Mol Cell 22 2 (2006 Apr 21) 159-168
128. Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., et al. Rapamycin derivatives reduce MTORC2 signaling and inhibit AKT activation in AML. Blood 109 8 (2007 Apr 15) 3509-3512
129. Plank T.L., Yeung R.S., and Henske E.P. Hamartin, the product of the tuberous sclerosis 1 (TSC1) gene, interacts with tuberin and appears to be localized to cytoplasmic vesicles. Cancer Res 58 21 (1998 Nov 1) 4766-4770
130. van Slegtenhorst M., Nellist M., Nagelkerken B., Cheadle J., Snell R., van den Ouweland A., et al. Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products. Hum Mol Genet 7 6 (1998 Jun) 1053-1057
131. Nellist M., van Slegtenhorst M.A., Goedbloed M., van den Ouweland A.M., Halley D.J., and van der Sluijs P. Characterization of the cytosolic tuberin-hamartin complex. Tuberin is a cytosolic chaperone for hamartin. J Biol Chem 274 50 (1999 Dec 10) 35647-35652
132. van Slegtenhorst M., de Hoogt R., Hermans C., Nellist M., Janssen B., Verhoef S., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science (New York, NY) 277 5327 (1997) 805-808
133. Rosner M., Freilinger A., and Hengstschlager M. Proteins interacting with the tuberous sclerosis gene products. Amino Acids 27 2 (2004 Oct) 119-128
134. Lamb R.F., Roy C., Diefenbach T.J., Vinters H.V., Johnson M.W., Jay D.G., et al. The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho. Nat Cell Biol 2 5 (2000 May) 281-287
135. Fukuhara S., and Gutkind J.S. A new twist for the tumour suppressor hamartin. Nat Cell Biol 2 5 (2000 May) E76-E78
136. The European Chromosome 16 tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 75 7 (1993) 1305-1315
137. Castro A.F., Rebhun J.F., Clark G.J., and Quilliam L.A. Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J Biol Chem 278 35 (2003 Aug 29) 32493-32496
138. Tee A.R., Manning B.D., Roux P.P., Cantley L.C., and Blenis J. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control MTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol 13 15 (2003 Aug 5) 1259-1268
139. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol 5 6 (2003 Jun) 578-581
140. Benvenuto G., Li S., Brown S.J., Braverman R., Vass W.C., Cheadle J.P., et al. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19 54 (2000 Dec 14) 6306-6316
141. Fingar D.C., Salama S., Tsou C., Harlow E., and Blenis J. Mammalian cell size is controlled by MTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16 12 (2002 Jun 15) 1472-1487
142. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses MTOR signalling. Nat Cell Biol 4 9 (2002 Sep) 648-657
143. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell 10 1 (2002 Jul) 151-162
144. Gao X., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol 4 9 (2002 Sep) 699-704
145. Goncharova E.A., Goncharov D.A., Eszterhas A., Hunter D.S., Glassberg M.K., Yeung R.S., et al. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 277 34 (2002 Aug 23) 30958-30967
146. Tee A.R., Fingar D.C., Manning B.D., Kwiatkowski D.J., Cantley L.C., and Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (MTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99 21 (2002 Oct 15) 13571-13576
147. Bai X., Ma D., Liu A., Shen X., Wang Q.J., Liu Y., et al. Rheb activates MTOR by antagonizing its endogenous inhibitor, FKBP38. Science 318 5852 (2007 Nov 9) 977-980
148. DeYoung M.P., Horak P., Sofer A., Sgroi D., and Ellisen L.W. Hypoxia regulates TSC1/2-MTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev 22 2 (2008 Jan 15) 239-251
149. Inoki K., Zhu T., and Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 115 5 (2003 Nov 26) 577-590
150. Sancak Y., Peterson T.R., Shaul Y.D., Lindquist R.A., Thoreen C.C., Bar-Peled L., et al. The Rag GTPases bind raptor and mediate amino acid signaling to MTORC1. Science 320 5882 (2008 Jun 13) 1496-1501
151. Huang J., Dibble C.C., Matsuzaki M., and Manning B.D. The TSC1-TSC2 complex is required for proper activation of MTOR complex 2. Mol Cell Biol 28 12 (2008 Jun) 4104-4115
152. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-MTOR complex. Science 307 5712 (2005 Feb 18) 1098-1101
153. Plas D.R., and Thomas G. Tubers and tumors: rapamycin therapy for benign and malignant tumors. Curr Opin Cell Biol 21 2 (2009 Apr) 230-236
154. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., and Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 6548 (1995 Oct 5) 441-446
155. Foster D.A. Phosphatidic acid signaling to MTOR: Signals for the survival of human cancer cells. Biochim Biophys Acta (2009 Mar 2)
156. Toschi A., Lee E., Xu L., Garcia A., Gadir N., and Foster D.A. Regulation of MTORC1 and MTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 29 6 (2009 Mar) 1411-1420
157. Noh D.Y., Ahn S.J., Lee R.A., Park I.A., Kim J.H., Suh P.G., et al. Overexpression of phospholipase D1 in human breast cancer tissues. Cancer Lett 161 2 (2000 Dec 20) 207-214
158. Zhao Y., Ehara H., Akao Y., Shamoto M., Nakagawa Y., Banno Y., et al. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer. Biochem Biophys Res Commun 278 1 (2000 Nov 11) 140-143
159. Uchida N., Okamura S., and Kuwano H. Phospholipase D activity in human gastric carcinoma. Anticancer Res 19 1B (1999 Jan-Feb) 671-675
160. Fang Y., Vilella-Bach M., Bachmann R., Flanigan A., and Chen J. Phosphatidic acid-mediated mitogenic activation of MTOR signaling. Science 294 5548 (2001 Nov 30) 1942-1945
161. Lee L., Sudentas P., Donohue B., Asrican K., Worku A., Walker V., et al. Efficacy of a rapamycin analog (CCI-779) and IFN-gamma in tuberous sclerosis mouse models. Genes Chromosomes Cancer 42 3 (2005 Mar) 213-227
162. Kenerson H., Dundon T.A., and Yeung R.S. Effects of rapamycin in the Eker rat model of tuberous sclerosis complex. Pediatr Res 57 1 (2005 Jan) 67-75
163. Bissler J.J., McCormack F.X., Young L.R., Elwing J.M., Chuck G., Leonard J.M., et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358 2 (2008 Jan 10) 140-151